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 39 
ABSTRACT 40 
Background: Bone gamma-carboxyglutamic acid (Gla)-protein (BGP or osteocalcin) is a vitamin 41 
K-dependent protein involved in the regulation of bone mineralization. Smoking is a risk factor for 42 
osteoporosis. 43 
Methods: We carried out a secondary analysis of the vitamin K Italian (VIKI) study to investigate 44 
the effects of cigarette smoking on BGP levels in patients with end stage renal disease. Data were 45 
collected in 370 haemodialysis patients, 37% (136) smokers (or ex-smokers) and 63% (234) non-46 
smokers. Vascular calcifications and vertebral fractures (quantitative morphometry) were identified 47 
on spine radiographs. 48 
Results: Smokers had significantly lower BGP levels (152 vs 204 μg/L, p= 0.003). Smokers had 49 
lower phosphate levels (4.25 (3.7, 5.3)) vs (4.86 (4.0, 5.6)) mg/dl, respectively, p= 0.008), albumin 50 
(3.8 (3.5, 4.0)) vs (3.9 (3.6, 4.2)) g/dL, respectively, p= 0.001). Lower BGP levels were associated 51 
with aortic calcification (p< 0.001), iliac calcification (p=0.042) and vertebral fractures (p=0.023).  52 
The regression model showed that smoking is associated with a significant reduction of total BGP 53 
levels by about 18% (p=0.01).  54 
Conclusion: This is the first clinical study in a haemodialysis population which identifies cigarette 55 
smoking as a potential inhibitor of BGP activity, a protective agent in bone and vascular health. 56 
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 59 
INTRODUCTION 60 
Bone gamma-carboxyglutamic acid (Gla)-protein (BGP), also called osteocalcin, is a small protein 61 
produced by osteoblasts under the control of vitamin D, which modulates the expression of BGP 62 
gene. Its specific affinity to bind hydroxyapatite molecules in bone is permitted by -carboxylated 63 
Gla residues [1]. As a result, carboxylated (Gla-containing) cBGP normalizes bone crystal 64 
nucleation [2]. BGP knockout mice exhibit a bone phenotype, characterized by small increases in 65 
cortical thickness (hyperostosis), and reduced bone strength, without differences in bone mineral 66 
content [3]. However, their bone contains immature hydroxyapatite crystals [4], indicating a role of 67 
BGP in promoting normal bone mineralization. Indeed, an in vitro study reported that osteoblasts 68 
markedly increase their expression of BGP under mineralizing conditions, compared with non-69 
mineralizing cultures [5], indicating that BGP regulates matrix mineralization.  70 
Smoking is a risk factor for osteoporosis [6] and vascular calcification [7]. Nicotine and non-71 
nicotine tobacco smoke components have been shown to depress osteoblast activity. Gao et al. 72 
showed that smoke exposure inhibited bone formation and increased bone resorption. Lumbar spine 73 
and femur Bone Mass Density (BMD) was lower in 4-month smoke-exposed female rats than 74 
controls. However, there was no significant difference in serum BGP levels between smoke-75 
exposed rats and controls [8].  76 
The objective of this secondary analysis of the vitamin K Italian (VIKI) study, an observational 77 
study designed to assess the prevalence of vitamin K deficiency in haemodialysis patients, was to 78 
assess the association between cigarette smoking and BGP levels in an end stage renal disease 79 
(ESRD) population. We hypothesized that BGP levels would be lower in smokers than never 80 
smokers, and that lower BGP levels would be related to fractures and severity of prevalent vascular 81 
calcification. 82 
 83 
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PATIENTS AND METHODS 84 
This study is a secondary analysis of the VIKI study, involving 18 dialysis centres in Italy [9]. All 85 
the local ethics committees approved the study, which was conducted according to the regulations 86 
in force related to observational studies. Approval dates ranged from July 14, 2008 to October 26, 87 
2009. Patient enrolment took place between November 2008 and November 2009, and follow-up to 88 
assess vital status was performed in December 2011. We included adult patients of both genders 89 
who had been on haemodialysis for >1 year, provided that they gave their informed consent, in 90 
writing, for the use of their medical records for the study. We excluded patients who had a life 91 
expectancy <6 months, cancer (with the exception of basal cell carcinoma), coagulation disorders, 92 
or conditions that according to the investigator could interfere with the study outcome. Study 93 
subjects were administered a questionnaire to ascertain smoking status (i.e. current, past or never 94 
smoker).  95 
Laboratory determination 96 
Parathyroid hormone (PTH)  97 
The method for quantitative determination of PTH in serum was the automated LIAISON® N-98 
Tact® PTH Assay 310910 (DiaSorin Inc., Stillwater MN, USA), a direct, 2-site, sandwich-type 99 
chemiluminescence immunoassay (CLIA) carried out on the LIAISON® (DiaSorin Inc., Stillwater 100 
MN, USA) instrument. The analytical sensitivity is 1 pg/mL and the intra-assay and inter-assay 101 
CVs were 3.7-6.3 and 3.5-5.3%, respectively.  102 
25-OH vitamin D  103 
For quantitative determination of total 25-OH vitamin D (both D2 and D3 form) in serum, we used 104 
the automated LIAISON® 25 OH Vitamin D TOTAL Assay 310600, a direct competitive CLIA 105 
executed on the LIAISON (Dia-Sorin Inc., Stillwater MN, USA) instrument. The analytical 106 
sensitivity is <10 nmol/L, and the intra-assay coefficients of variation (CV) were between 2.9 and 107 
5.5%, while the inter-assay CV is 6.3-12.9%.  108 
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Total BGP  109 
The method for the quantitative determination of total BGP in serum was the automated 110 
LIAISON® Osteocalcin Assay 310950 (DiaSorin Inc., Stillwater MN, USA), a direct, 2-site, 111 
sandwich-type CLIA executed on the LIAISON® (Dia- Sorin Inc., Stillwater MN, USA) 112 
instrument. The analytical sensitivity is <0.3 ng/mL and the intra-assay CV is 3-8%, while the inter-113 
assay CV is 4-9%.  114 
Undercarboxylated BGP (ucBGP)  115 
For quantitative determination of the undercarboxylated form, we used Glu-osteocalcin Enzyme 116 
Immuno Assay (EIA) Kit MK118 (Takara Bio Inc., Otsu, Shiga, Japan), a manual solid-phase EIA 117 
based on a sandwich method that utilizes 2 mouse monoclonal anti-ucBGP antibodies to detect 118 
ucBGP by a 2-step procedure. One of the mouse monoclonal anti-undercarboxylated BGPs is 119 
immobilized onto the micro-titre plate and blocked against non-specific binding. Samples are added 120 
to each well and incubated. The second step is to wash the plate and to add the second anti-BGP 121 
labelled with peroxidase (POD). The reaction between POD and substrate (H2O2 and 3,3
’, 5,5’ 122 
tetramethyl-benzidine) results in colour development with intensities proportional to the amount of 123 
ucBGP present. The analytical sensitivity is 0.25 ng/mL and the intra-assay and inter-assay CVs are 124 
4.4-6.7 and 5.7-9.9%, respectively.  125 
Vertebral fractures and vascular calcification assessment 126 
A radiograph of the thoracic and lumbar regions of the spinal column (D5 to L4) in the latero-lateral 127 
view with the patient in the lateral recumbent position was obtained. A vertebral fracture (VF) was 128 
considered to be present when the height of the vertebral body was reduced by at least 20% (4 mm) 129 
[10]. 130 
Vascular calcifications (VC) were quantified by measuring the length of calcific deposits along the 131 
abdominal aortic wall (mild 0.1-5 cm, moderate 5.1-10 cm and severe >10 cm). The presence of 132 
calcifications of the iliac arteries was evaluated through the same radiograph (mild 0.1-3 cm, 133 
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moderate 3.1-5 cm, and severe >5 cm) [11]. 134 
Statistical analysis  135 
The data are shown as mean ± standard deviation (SD) for quantitative variables or median and 136 
interquartile range (IQ) for not normal or strongly asymmetric variables, and frequency percentages 137 
for all discrete variables. Normal distribution of continuous variables was tested using the Shapiro-138 
Wilk test. For discrete variables, the differential distribution between present or past smokers and 139 
non-smokers was analysed by χ2 test or Fisher’s exact method. For quantitative variables, the 140 
comparisons were evaluated using Generalized Linear Models (Levene’s test was performed to test 141 
the homoschedasticity; when its assumption was violated, the Welch’s ANOVA was used) or the 142 
non-parametric Wilcoxon sum rank test. 143 
Multiple regression models were defined, to assess the strength of the association between total and 144 
undercarboxylated BGP (outcomes) and smoking status; each outcome underwent logarithmic 145 
transformation. Among available variables (gender, age, renal failure history, alcohol consumption, 146 
medical history (cardio- and cerebrovascular disease, diabetes mellitus, malabsorption syndrome 147 
and liver disease), BMI, results from routine biochemical examinations, and mineral and bone 148 
disorders treatment (oral calcitriol, vitamin D analogues, calcimimetics, and phosphate-binding 149 
drugs)), factors included as independent variables were those associated with the outcome at the 150 
univariate level (p≤0.10) or associated with smoking status (p≤0.10). 151 
All statistical analyses were performed using SAS statistical package (version 9.3, SAS, Cary, NC).  152 
 153 
RESULTS 154 
Cohort characteristics by smoking status (Table 1). 155 
Data on smoking status were collected in 370 patients: 136 (36.8%) were current or former smokers 156 
and 234 (63.2 %) never smoked. Current and former smokers were more commonly men, had 157 
greater use of alcohol, and had greater prevalence of angina (23.5 vs 13.2%, p=0.011) and 158 
myocardial infarction (27.2 vs 15.0%, p=0.006). Smokers also had lower levels of phosphate [4.25 159 
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(3.72, 5.30)] vs [4.86 (4, 5.58)] mg/dl respectively, p= 0.008), albumin [3.8 (3.5, 4.0)] vs [3.9 (3.6, 160 
4.2)] g/dL respectively, p= 0.001). 161 
Variables associated with BGP levels 162 
Total but not undercarboxylated levels of BGP were lower in smokers than non-smokers (152 vs 163 
204 μg/L, p= 0.003). Stratification by gender demonstrated that median [IQR] levels of BGP were 164 
lower in male smokers [147 μg/L (83.8, 247)] compared with non-smokers [206 μg/L (97.2, 165 
355.3)], p = 0.005. In contrast, differences between female smokers [187 μg/L (107, 361.9)], and 166 
non-smokers [204 μg/L (115, 403.3)] were not significant, p = 0.79. In linear regression modelling, 167 
adjusted for gender, age, BMI, alcohol consumption, angina, myocardial infarction, atrial 168 
fibrillation, heart failure, cerebrovascular accidents, diabetes mellitus, vertebral fractures, 169 
calcifications, biochemical profile (P, Ca-P product, albumin, high-density lipoprotein (HDL) 170 
cholesterol, alkaline phosphatase (ALP), parathyroid hormone (PTH), C-reactive protein (PCR), 171 
drugs (vitamin D analogues, calcimimetics, warfarin, steroids, antibiotics, insulin, statins), a history 172 
of smoking was associated with an 18% lower level of median BGP, and smoking accounted for 173 
53% of the variability in BGP levels (parameter estimate -0.199; p = 0.0105; R2 = 0.53). Other 174 
variables significantly associated with BGP were found to be atrial fibrillation (parameter estimate -175 
0.374, p=0.0010), diabetes mellitus (-0.328, p=0.0108), age (-0.010, p=0.0006), BMI (-0.0375, 176 
p<0.0001), alkaline phosphatase (0.349, p<0.0001), PTH (0.234, p<0.0001), calcimimetics (0.308, 177 
p=0.0005) and warfarin use (-0.429, p=0.0002); gender was not significantly associated with BGP 178 
(p=0.5761). 179 
Relationships between BGP, vascular calcifications and fractures  180 
We also explored relationships between vascular calcifications, vertebral fracture, smoking status 181 
and BGP. Calcifications of the abdominal aorta and iliac arteries were present in 79.7% and 54.9% 182 
of our cohort, respectively. Prevalence of calcifications at both sites were similar between groups 183 
regardless of smoking history. Lower total BGP levels were associated with aortic (p< 0.001) and 184 
iliac (p=0.042) calcification, and severe aortic vascular calcifications were associated with lower 185 
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total BGP levels (218 vs 165 μg/L, p=0.002). Vertebral fractures were prevalent in 54% of patients 186 
and did not differ by smoking status. Lower total levels of BGP were associated with vertebral 187 
fractures (p=0.023) (Figure 1). 188 
 189 
DISCUSSION  190 
This study shows a significant association of BGP and cigarette smoking, especially in males, as 191 
well as a possible protective role of BGP in bone metabolism and vascular health. To our 192 
knowledge, this is the first clinical study conducted in a haemodialysis population suggesting that 193 
smoking interferes with BGP activity and therefore bone and vascular health.  194 
The carboxylation of BGP is responsible for protein activation in bone tissue, while the 195 
undecarboxylated form (ucBGP) seems to be less important for bone metabolism and more active in 196 
extra-skeletal sites [12]. In fact, BGP may be involved in the aortic calcification process indirectly 197 
by its action on insulin, in particular in the presence of metabolic acidosis with bone resorption, 198 
where an increase of ucBGP is observed. ucBGP is able to promote the secretion of insulin from 199 
pancreatic beta-cells [13]. Moreover, BGP may also induce the release of adiponectin, an anti-200 
inflammatory adipokine secreted by adipocytes, as described in mice [14] and chronic kidney 201 
disease (CKD) patients [15]. Adiponectin is able to prevent the transdifferentiation of vascular 202 
smooth muscle cells (VSMCs) into osteoblast-like cells in arterial vessels [16]. On the other hand, 203 
an in vitro study suggested the BGP overexpression may be associated with increased cartilage and 204 
vascular calcification with a hypoxia-inducible factor 1 mediated mechanism [17].  205 
In humans, a 10 years prospective study in elderly Caucasian men showed that BGP levels might be 206 
an independent indicator of cardiovascular risk and mortality, with higher total BGP concentrations 207 
being associated with lower abdominal aortic calcification (AAC) progression rate and lower 208 
mortality [18]. Moreover, we showed that low levels of BGP are associated to vertebral fracture 209 
(VF), aortic and iliac calcifications [19]. 210 
We showed that vitamin D analogues and calcimimetics are able to improve vitamin K dependent 211 
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protein levels. In particular, calcimimetics and vitamin D analogues use was associated with 212 
increased BGP levels in haemodialysis patients, suggesting a role of these drugs in preserving 213 
vitamin K-dependent protein activity, thus contributing to bone and vascular health in CKD patients 214 
[20].  215 
Nowadays, smoking is widely prevalent and is known to be strictly connected with cardiovascular 216 
disease by promoting vascular damage and progression of arterial ageing: for example, smoking 217 
stimulates the formation of reactive oxygen radical species and oxidative stress, inducing early 218 
vascular ageing [21].  219 
Some studies have identified smoking as a risk factor for osteoporosis, showing inhibition of 220 
osteoblast activity both in vitro and in animal studies [8]. In humans, meta-analyses of the effects of 221 
smoking on bone status demonstrated decreased bone mass in current smoker compared with non-222 
smoker populations [22, 23]. Nevertheless, the effect of nicotine on bone remains controversial; the 223 
negative impact of smoking on bone status might be associated to cigarette smoke constituents 224 
(such as toxic heavy metals, polychlorinated biphenyls, dioxin, polycyclic aromatic hydrocarbons) 225 
other than nicotine alone [24].    226 
By the regression model, we found that smokers had levels of BGP that were about 20% lower than 227 
those of patients who never smoked. In our model, gender was not significantly associated with 228 
total BGP. To our knowledge, data about the relationship between smoking and BGP are limited in 229 
human populations. Available studies suggested that smoking could be associated with depressed 230 
osteoblast activity and with reduced BGP gene expression in humans. In particular, consistent with 231 
our findings, Laroche et al. observed that BGP levels were significantly lower in smokers than in 232 
non-smokers; the difference was significant in males but not in females [25,26].  233 
Chassanidis et al. identified in smokers a remarkable decrease of the gene expression of BMP-2, -4, 234 
and -6, which play an important role in the maintenance of bone mass, resulting in reduced BGP 235 
synthesis [27]. 236 
Another study highlighted that cigarette smoke extract can lead to inhibition of osteoblastic 237 
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differentiation of cultured human periosteum-derived cell, as well as inhibition of alkaline 238 
phosphatase activity, mineralization and Runx2 transactivation of the periosteum-derived cells. The 239 
role of BGP was not investigated [28]. 240 
In conclusion, we report for the first time a significant association between smoking and lower BGP 241 
levels in males affected by advanced CKD. In the same population, low BGP levels are associated 242 
with fractures and vascular calcifications. Larger longitudinal studies should evaluate the effects of 243 
smoking on BGP activity and their consequences on bone and vascular health. 244 
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Table 1. Main patient characteristics.  329 
 
Patients 
Smoker or ex-smoker 
(n=136) 
Patients 
Non-Smoker 
(n=234) 
p 
Gender, female, n (%) 31 (22.8 %) 108 (46.2 %) < 0.001 
Age, years, mean ± standard deviation  65.4± 3.5 63.6 ±14.4 0.241 
Weight, kg, mean ± standard deviation 72.7±14.9 68.8±14.0 0.012 
Height, m, mean ± standard deviation 1.69±0.09 1.66±0.09 0.001 
Height, m, median 1.70 (1.62, 1.75) 1.65 (1.60, 1.72) < 0.001 
Body mass index (BMI), kg/m2, mean ± 
standard deviation 
25.3±4.3 24.9±4.4 0.411 
Current or former alcohol drinker, n (%) 56 (41.2%) 24 (10.3%) < 0.001 
    
Medical history    
Dialysis vintage, months, median 45 (26.5, 77.5) 52 (29, 99) 0.105 
Type of dialysis, n (%) 
Bicarbonate dialysis 
Haemofiltration (HF) 
Haemodiafiltration (HDF) 
Acetate free biofiltration (AFB) 
 
59 (43.4%) 
10 (7.4%) 
43 (31.6%) 
21 (15.4%) 
 
118 (50.4%) 
22 (9.5%) 
56 (23.9%) 
31 (13.2%) 
0.448 
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Patients 
Smoker or ex-smoker 
(n=136) 
Patients 
Non-Smoker 
(n=234) 
p 
Other types of dialysis 3 (2.2%) 7 (3.0%) 
Previous kidney transplant, n (%) 13 (9.6%) 36 (15.4%) 0.111 
Hypertension, n (%) IPA 111 (81.6%) 177 (75.6%) 0.182 
Angina, n (%) 32 (23.5%) 31 (13.2%) 0.011 
Myocardial infarction, n (%) 37 (27.2%) 35 (15.0%) 0.006 
Atrial fibrillation, n (%) 14 (10.3%) 35 (15.0%) 0.202 
Heart failure, n (%) 20 (14.7%) 17 (7.3%) 0.222 
Diabetes Mellitus, n (%) 35 (25.7%) 47 (20.1%) 0.207 
Peripheral arterial disease, n (%) 
None 
Asymptomatic 
Intermittent claudication 
Amputation 
 
84 (61.8%) 
35 (25.7%) 
14 (10.3%) 
3 (2.2%) 
 
160 (68.4%) 
56 (23.9%) 
13 (5.6%) 
5 (2.1%) 
0.343 
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Patients 
Smoker or ex-smoker 
(n=136) 
Patients 
Non-Smoker 
(n=234) 
p 
Cerebrovascular accident, n (%) 
None 
Stroke 
Other type 
 
118 (50.0%) 
12 (8.8%) 
6 (4.4%) 
 
216 (92.3%) 
7 (3.0%) 
11 (4.7%) 
0.050 
Vertebral fractures, n (%) 74 (54.4%) 127 (54.3%) 0.979 
Vertebral fractures among men, n (%) 59 (43.4%) 78 (33.3%) 0.379 
Vertebral fractures among women, n (%) 15 (48.4%) 49 (45.4%) 0.766 
Aortic calcifications, n (%) 115 (84.6%) 180 (76.9%) 0.078 
Iliac calcifications, n (%) 71 (52.2%) 132 (56.4%) 0.433 
    
Routine biochemical profile    
Calcium, mg/dl, mean ± standard deviation 9.098±0.526 9.181±0.709 0.199 
Phosphate, mg/dl, median 4.25 (3.72, 5.30) 4.70 (4, 5.58) 0.008 
Alkaline phosphatase, U/L, median 85.50 (64.50, 111.50) 83.50 (65, 112) 0.582 
Parathyroid hormone (PTH), pg/ml, 
median 
248.5 (140, 411) 243.5 (140, 381) 0.777 
Albumin, g/dl, median 3.8 (3.5, 4.0) 3.9 (3.6, 4.2) 0.001 
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Patients 
Smoker or ex-smoker 
(n=136) 
Patients 
Non-Smoker 
(n=234) 
p 
C-reactive protein (PCR), mg/L, median 1.50 (0.42, 4.76) 1.90 (0.52, 5.50) 0.476 
Kt/V mean ± standard deviation 1.22 ± 0.28 1.28 ± 0.27 0.056 
Aluminium, mcg/L, median 
12.5 (7.1, 20)  
(for 60 patients) 
12 (8, 21)  
for (104 patients) 
0.806 
Total cholesterol, mg/dl, median 164.50(139.5, 190.5) 169.5 (144, 195) 0.587 
Triglycerides, mg/dl, median 159 (109, 206) 142.5 (113, 208) 0.588 
High-density lipoprotein (HDL) 
Cholesterol, mg/dl, median 
39 (32, 49) 41 (33, 51.5) 0.071 
Low-density lipoprotein (LDL) 
Cholesterol, mg/dl, median 
90 (70, 116) 91 (70, 117) 0.920 
25(OH)-vitamin D, median 27.9 (17.3, 42.6) 29.9 (20.1, 46) 0.131 
Bone Gla-protein (BGP) total, μg /L, 
median 
152.00 (91.70, 251) 204.50 (111, 362) 0.003 
Bone Gla-protein (BGP) 
undercarboxylated, μg /L, median 
10.37 (4.01,16.10) 11.09 (5, 21.23) 0.212 
330 
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 331 
Figure. 1. Median total BGP levels and association with (a) vertebral fractures, (b) aortic 332 
calcification, and, (c) iliac calcification.  333 
(a) 334 
 335 
(b) 336 
 337 
(c) 338 
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 341 
SUPPLEMENT TABLE 1. Therapy. 342 
 343 
Drugs prescribed to patients  
Patients 
Smoker or ex-smoker 
(n=136) 
Patients 
Non-Smoker 
(n=234) 
p 
Warfarin (n, %) 16 (11.8%) 28 (12.0%) 0.954 
Steroid (n, %) 3 (2.2%)  17 (7.3%) 0.038 
Thyroid Hormones (n, %) 16 (11.8%)  20 (8.5%)  0.314 
Antibiotics (n, %) 7 (5.1%) 9 (3.8%) 0.553 
Antiepileptic (n, %) 7 (5.1%) 6 (2.6%) 0.193 
Statin Therapy (n, %) 58 (42.6%) 67 (28.6%) 0.006 
Beta-Blockers (n, %) 43 (31.6%) 92 (39.3%) 0.138 
 21 
Antidiabetics (n, %) 2 (1.5%) 4 (1.7%) 0.861 
Insulin (n, %) 25 (18.4%) 31 (13.2%) 0.184 
Anti-Gastric (n, %) 108 (79.4%) 180 (76.9%) 0.822 
Aluminium (n, %) 21 (15.4%) 74 (31.6%) 0.001 
Calcium Carbonate (n, %) 52 (38.2%) 76 (32.5%) 0.262 
Calcium Acetate (n, %) 9 (6.6%) 10 (4.3%) 0.325 
Sevelamer (n, %) 55 (40.4%) 100 (42.7%) 0.666 
Lanthanum (n, %) 22 (16.2%) 33 (14.1%) 0.589 
Oral Calcitriol (n, %) 65 (47.8%) 103 (44.0%) 0.482 
Intravenous Calcitriol (n, %) 6 (4.4%) 5 (2.1%) 0.214 
Vitamin D Analogues (n, %) 20 (14.7%) 54 (23.1%) 0.052 
Calcimimetics (n, %) 28 (20.6%) 45 (19.2%) 0.752 
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